GS1-144

1. GS1-144 decreases luteinizing hormone in silico.

   “GS1-144 produced dose-dependent LH suppression across once-daily and twice-daily regimens.”

   In silicoModel-based simulations in postmenopausal womenserum30, 45, 60, and 90 mg once daily; 15, 30, and 60 mg twice daily7 daysfemales

   Population pharmacokinetic-pharmacodynamic modeling and dose selection of GS1-144 based on luteinizing hormone suppression in postmenopausal women

   Journal of pharmacokinetics and pharmacodynamics·16 Oct 2026

More on Luteinizing hormone